Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE; 'Sumitomo Dainippon Pharma') announced today that it has resolved to merge its consolidated subsidiaries in the United States, Boston Biomedical, Inc. 'Boston Biomedical' and Tolero Pharmaceuticals, Inc. 'Tolero' scheduled on July 1, 2020 and to change the company name to Sumitomo Dainippon Pharma Oncology, Inc.

Objective of the merger

Boston Biomedical and Tolero are both engaged in research and development of oncology. Consolidation of the two companies is aimed at further increasing corporate value through improvement of business efficiency, efficient use of management resources, increase in our market presence, and further strengthening of cooperation with external partners

Contact:

Tel: +81-6-6203-1407

Financial impact on group performance Because the merger is between two of our consolidated subsidiaries, the impact on our consolidated results will be minimal.

(C) 2020 Electronic News Publishing, source ENP Newswire